Source: Pharmabiz

XBiotech: XBiotech begins patient enrolment in French National Cancer Institute sponsored phase I/II/III study for Natrunix therapy for colorectal cancer

XBiotech announced the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with trifluridine/tipiracil for the treatment of colorectal cancer. The much

Read full article »
Annual Revenue
John Simard's photo - Chairman & CEO of XBiotech

Chairman & CEO

John Simard

CEO Approval Rating


Read more